Ireland’s established strength in pharmaceuticals and medtech is creating a broader opportunity as healthcare becomes increasingly connected. The latest focus on AgeTech highlights how pharma, digital health, AI, medical devices and data are coming together, giving companies a wider ecosystem in which to develop, test and scale new healthcare solutions.

In its latest insight, IDA Ireland identifies the convergence of MedTech, digital health, AI and financial services as a particular opportunity for AgeTech companies choosing where to expand. The IDA Ireland analysis points to more than 300 medtech companies operating in Ireland, employing close to 50,000 people, alongside a multinational base that includes 14 of the world’s top 15 medtech companies and nine of the top 10 pharmaceutical companies. For pharma, that combination provides an established industrial environment in which emerging technologies can connect with manufacturing expertise, research capability and global companies.

The opportunity extends beyond ageing-related products. As medicines become increasingly connected to diagnostics, monitoring technologies and digital services, pharmaceutical companies are becoming part of broader patient pathways rather than operating around the medicine alone. Ireland’s national AI for Care strategy, published by the Department of Health in March 2026, provides further evidence of this shift. The strategy sets out how AI can be used across clinical care, operations, research and innovation, and public health, creating a stronger foundation for the adoption of data-driven healthcare.

That infrastructure creates practical opportunities for the pharma sector. AI-enabled clinical workflows, remote monitoring, digital therapeutics, data platforms and more connected clinical research models can all support how medicines are developed and delivered. The Department of Health’s strategy also identifies research and innovation, including the use of health data for discovery, population health and clinical trials, as an important part of Ireland’s AI ambitions. This strengthens the potential for pharmaceutical companies to work alongside technology providers, healthcare organisations and research groups.

Ireland’s growing use of virtual care provides a tangible example of this ecosystem developing in practice. The HSE’s Virtual Wards programme is now operating across all six health regions, allowing suitable patients to receive hospital-level care at home with clinical teams using digital tools. More than 3,000 patients have been supported through the programme since its launch in 2024. For pharma, developments such as these show how digital technologies are becoming embedded within real healthcare pathways rather than remaining separate innovation projects.

This convergence also creates an opportunity to think more broadly about pharmaceutical value. Connected care can support patient monitoring, adherence, clinical-trial recruitment and real-world evidence, while partnerships with medtech and technology companies can open new routes for combining medicines with digital and device-based services. Ireland’s relatively compact ecosystem, highlighted by IDA Ireland, can help bring multinational companies, scaling businesses, research organisations and healthcare stakeholders into closer proximity.

The sector takeaway is that Ireland’s life-sciences opportunity is becoming broader than its established reputation as a pharmaceutical manufacturing base. The convergence of pharma, medtech, AI and digital health is creating a more connected environment for innovation, collaboration and commercialisation. For pharmaceutical companies developing the next generation of patient-centred solutions, Ireland’s ability to bring these capabilities together could become an increasingly important competitive advantage.